Anlageziel

This Sub-Fund aims to achieve capital growth in USD. While respecting the principle of risk diversification, the Sub-Fund’s assets are primarily invested in equities, equity-like transferable securities, participation certificates etc. issued by particularly innovative small, mid and large cap biotech companies worldwide which are active in the human medicine sector and depositary receipts, such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and European Depositary Receipts (EDRs), referring to such securities. While no geographical restrictions apply re. specific countries or regions, the industry and therefore the Sub-Fund’s investments are centered in North America and Western Europe.